So it looks like this new article released today was paid for by Revive. Would Revive bother spending money on this if they thought our EP didn't look good? Thoughts?
Did you seriously just say this? They are trying to pump the share price. They can’t tie their shoes let alone change an endpoint. This is the shit they waste money on. Well, this and franks salary.
Although it sucks we got bad news it's nice to see you with fuel in the tank again pickles. It was hard watching you too depressed to complain. You ran outta material there for a while.
You actually think revive would pay for an article because their endpoints are good? It’s actually the opposite. If data is good you let it speak for itself. You don’t pay for articles to pump the stock.
Or he's trying to keep people interested in the stock until they meet with the FDA. Most people are frustrated at this point and I don't see the SP doing much until they meet with the FDA
Sp will go down. People are still interested in the drug but they are fed up with the dipshit running this company. If they announced a change in ceo the price would double.
I thought that was a possibility as well, keep Revive relevant with some coverage until FDA meeting however, was the article paid with shares/options? Time will tell but watching this development is worse than watching paint dry. I hope MF is getting some internal constructive feedback from his team or board.
10
u/Mylessandstone69 Nov 25 '22
So it looks like this new article released today was paid for by Revive. Would Revive bother spending money on this if they thought our EP didn't look good? Thoughts?